Roche has entered into a definitive merger agreement to acquire Poseida Therapeutics, a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies.  Roche will acquire the company for $9 per share in cash at closing, representing a total equity value of approximately $1 billion.  Stockholders would also receive a non-tradeable contingent value right (CVR) for up […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!